拉考沙胺、普瑞巴林与他喷他多对外周神经兴奋性的影响:健康受试者随机双盲安慰剂对照交叉多中心试验
该随机双盲安慰剂对照交叉试验纳入43名健康受试者,评估单次口服拉考沙胺200 mg、普瑞巴林150 mg、他喷他多100 mg对高频刺激诱发痛觉过敏后外周神经兴奋性的影响。主要终点为给药后60分钟时大感觉纤维和运动纤维的强度-时限时间常数(SDTC)较基线的变化。拉考沙胺显著降低大感觉纤维和运动纤维的SDTC,而普瑞巴林和他喷他多对SDTC无影响。
要点
- 拉考沙胺显著降低健康受试者大感觉纤维和运动纤维的SDTC。
- 普瑞巴林和他喷他多对SDTC无显著影响。
- 神经兴奋性测试可检测药物对大髓鞘纤维的药效学效应。
核心结论
- 拉考沙胺显著降低外周神经兴奋性,尤其在大感觉纤维。
- 神经兴奋性测试可检测健康受试者大髓鞘纤维的药效学效应。
研究设计与样本
- 随机、双盲、安慰剂对照、交叉、多中心试验,纳入43名18至45岁健康受试者。
- 受试者接受单次拉考沙胺200 mg、普瑞巴林150 mg、他喷他多100 mg或安慰剂,共四个治疗期。
- 高频刺激诱导痛觉过敏,主要终点为给药后60分钟大感觉纤维和运动纤维的SDTC较基线变化。
主要发现
- 拉考沙胺显著降低大感觉纤维SDTC(平均降低0.04;95%CI 0.01至0.08;P=0.012)。
- 拉考沙胺显著降低运动纤维SDTC(平均降低0.04;95%CI 0.00至0.07;P=0.039)。
- 拉考沙胺对小时感觉纤维SDTC无影响。
- 普瑞巴林和他喷他多对SDTC无影响。
- 拉考沙胺在大感觉纤维中引起亚兴奋性、S2适应TEd(peak)和TEd40(Accom)的显著变化。
关键数值与推荐
- 拉考沙胺200 mg单次给药后60分钟,大感觉纤维SDTC平均降低0.04(95%CI 0.01至0.08;P=0.012)。
- 拉考沙胺200 mg单次给药后60分钟,运动纤维SDTC平均降低0.04(95%CI 0.00至0.07;P=0.039)。
- 普瑞巴林150 mg和他喷他多100 mg单次给药对SDTC无显著影响。
临床怎么用
- 神经兴奋性测试可作为评估药物对外周大髓鞘纤维药效学的生物标志物。
- 拉考沙胺对外周神经兴奋性的降低作用可在健康受试者中通过SDTC检测。
局限性
- 研究仅纳入健康受试者,结论不能直接外推至慢性疼痛患者。
- 单次给药设计无法评估长期用药效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic pain is a leading cause of disability globally, with limited treatment options and frequent adverse effects. The IMI-PainCare-BioPain project aimed to enhance analgesic drug development by standardizing biomarkers. This study, IMI2-PainCare-BioPain-RCT1, evaluated the effects of lacosamide, pregabalin, and tapentadol on peripheral nerve excitability in healthy subjects through a randomized, double-blind, placebo-controlled crossover trial. METHODS: The study included 43 healthy participants aged 18 to 45 yr. Participants underwent four treatment periods during which they received single doses of lacosamide (200 mg), pregabalin (150 mg), tapentadol (100 mg), or placebo. High-frequency stimulation was applied to induce hyperalgesia. The two primary endpoints were changes in strength-duration time constant (SDTC) in large sensory and motor fibers between lacosamide and placebo periods at the first postdose timepoint compared to baseline (60 min). Other predefined endpoints included recovery cycle, threshold electrotonus (TEd), and S2 accommodation, as well as effects of pregabalin and tapentadol. RESULTS: Lacosamide statistically significantly reduced SDTC in large sensory fibers (mean reduction, 0.04; 95% CI, 0.01 to 0.08; P = 0.012) and in motor fibers (mean reduction, 0.04; 95% CI, 0.00 to 0.07; P = 0.039) but had no effect on small sensory fibers at the first timepoint compared to placebo. There were no effects of pregabalin and tapentadol on SDTC. Of other predefined endpoints, lacosamide produced statistically significant changes in subexcitability, S2 accommodation TEd(peak), and TEd40(Accom) in large sensory fibers. No statistically significant changes were observed in refractoriness, relative refractory period, or accommodation half-time at the first timepoint compared to placebo. CONCLUSIONS: This study demonstrates that nerve excitability testing can detect pharmacodynamic effects on large myelinated fibers in healthy subjects. Lacosamide statistically significantly reduced peripheral nerve excitability, particularly in large sensory fibers.
引用
- Nochi Z, Pia H, Bloms-Funke P, et al. Effects of Lacosamide, Pregabalin, and Tapentadol on Peripheral Nerve Excitability: A Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Trial in Healthy Subjects. Anesthesiology. 2025. PMID: 40758952. doi:10.1097/ALN.0000000000005694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。